Clinical Trials Directory

Trials / Withdrawn

WithdrawnNCT01441284

Efficacy of Pramipexole Extended Release in the Treatment of Essential Tremor

Efficacy of Pramipexole Extended Release in the Treatment of Essential Tremor: a Double-blind, Cross-over, Placebo-controlled Multicenter Study

Status
Withdrawn
Phase
Phase 3
Study type
Interventional
Enrollment
0 (actual)
Sponsor
University of Pecs · Academic / Other
Sex
All
Age
18 Years – 80 Years
Healthy volunteers
Not accepted

Summary

Aim of the study is to perform a double-blind, crossover, placebo-controlled multicenter study evaluating the efficacy of pramipexole on essential tremor.

Detailed description

Essential tremor is one of the most common movement disorders with the prevalence of 3-5% among the elderly population. Although its main clinical feature is the bilateral, predominantly postural-kinetic tremor, newer studies suggest that ET is a spectrum of clinical features with both motor and nonmotor elements not homogeneously distributed. Despite its high occurrence, the pharmacological treatment of ET is limited. Although the mainline drugs, propranolol and primidone, can provide good clinical benefit in a portion of cases, \>50% of the patients stop the medication due to inefficacy or side-effects. Hypotension, dizziness, bradycardia, cognitive impairment, fatigue and erectile dysfunction are the most common side-effects contributing to medication discontinuation. In an open-label pilot study, the investigators previously demonstrated that 2.1 mg/day pramipexole extended-release improved both the severity of tremor (by 52%) and health-related quality of life. The present study aims to confirm this hypothesis in a double-blind, crossover, placebo-controlled multicenter study.

Conditions

Interventions

TypeNameDescription
DRUGpramipexolepramipexole extended release, 2.1 mg pramipexole base (3.0mg pramipexole salt) once daily
DRUGplaceboplacebo

Timeline

Start date
2017-12-01
Primary completion
2018-12-01
Completion
2018-12-01
First posted
2011-09-27
Last updated
2017-05-08

Locations

2 sites across 1 country: Hungary

Source: ClinicalTrials.gov record NCT01441284. Inclusion in this directory is not an endorsement.